Investigation and analysis of the status of cancer health popularization in China,2023

BACKGROUND Cancer presents a significant public health challenge in China,necessitating broad collaboration across society.The Chinese government has articulated a goal to increase the overall five-year survival rate for cancer by 15%by 2030.Achieving this objective requires not only advances in medical technology,but also an im-provement in the dissemination of knowledge pertaining to cancer prevention and treatment.AIM To provide a comprehensive understanding of the status of cancer prevention and level of popularization in China in 2023.METHODS From January 2023 to May 2023,online questionnaires were distributed to 3000 participants,including medical personnel,patients with cancer,their families,and the general public.There were 2711 valid responses,covering the entire nation.RESULTS A total of 1020 medical personnel and 1691 patients with cancer,their family members,and the general public participated in the survey.Among medical personnel,93.2%had popularized cancer health.Commonly addressed topics included cancer prevention(85.9%)and cancer screening(77.8%).Primary challenges included time constraints(73.9%),insufficient personnel and material support(66.7%),and uncertainty as to where to begin(49.3%).Among patients with cancer,their family members,and the general public,93.4%reported reading or watching cancer science popularization materials and 56.9%expressed a desire for deeper understanding.The most sought-after topics in cancer science popularization included cancer screening(80.2%)and cancer prevention(75.8%).The greatest challenge encountered in accessing cancer health popularization was an abundance of misinformation(67.5%).CONCLUSION Most clinical doctors,patients,family,and the general public wish to participate in cancer education.However,improvement in the quality of content in cancer prevention and treatment education is required.

Survival nomograms for simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy in patients with resectable colorectal liver metastasis

Background No well-performing nomogram has been developed specifically to predict individual-patient cancer-specific survival(CSS)and overall survival(OS)among patients with resectable colorectal liver metastasis(CRLM)who undergo simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy(NAC).We aim to investigate the prognosis of patients with resectable CRLM undergoing simultaneous resection of primary and hepatic lesions without NAC.Methods Data of patients with CRLM in the Surveillance,Epidemiology and End Results Program(cohort,n=225)were collected as the training set,and data of patients with CRLM treated at the National Cancer Center(cohort,n=180)were collected as the validation set.The prognostic value of the clinicopathological parameters in the training cohort was assessed using Kaplan‒Meier curves and univariate and multivariate Cox proportional hazards models,and OS and CSS nomograms integrated with the prognostic variables were constructed.Calibration analyses,receiver operating characteristic(ROC)curves,and decision curve analyses(DCAs)were then performed to evaluate the performance of the nomograms.Results There was no collinearity among the collected variables.Three factors were associated with OS and CSS:the pretreatment carcinoembryonic antigen(CEA)concentration,pathologic N(pN)stage,and adjuvant chemotherapy(each p<0.05).OS and CSS nomograms were constructed using these three parameters.The calibration plots revealed favorable agreement between the predicted and observed outcomes.The areas under the ROC curves were approximately 0.7.The DCA plots revealed that both nomograms had satisfactory clinical benefits.The ROC curves and DCAs also confirmed that the nomogram surpassed the tumor,node,and metastasis staging system.Conclusion The herein-described nomograms containing the pretreatment CEA concentration,pN stage,and adjuvant chemotherapy may be effective models for predicting postoperative survival in patients with CRLM.